

Full-Life Technologies Launches with \$10M Seed Round Financing to Advance Its Nuclear Technology & Nuclear Medicines Businesses

December 21, 2021, Belgium and Shanghai, China: Full-Life Technologies (“Full-Life”) today announced a \$10 million seed round financing to advance the development of its broad pipeline of Precision Nuclear Medicines as well as its Nuclear Technology platform to address supply chain challenges in Nuclear Medicine. Chengwei Capital was the sole & lead investor and Full-Life was co-founded by Gordian Ventures.

“Nuclear medicine is one of the most validated and attractive opportunities within targeted cancer therapeutics, with potential to unlock tremendous clinical value for patients globally” said Dr Nicholas Wong, Ph.D., Full-Life’s Co-founder & Chief Operating Officer. “Full-Life is positioned as one of the only companies developing end-to-end solutions for nuclear therapeutics with a vision to couple the latest techniques in production and logistics with cutting edge drug discovery approaches.”

Nuclear Medicine has seen a renaissance in recent years with significant clinical and commercial validation in some of the most challenging cancers. The field still represents an underinvested area where additional drug discovery efforts are critical to rapidly bring novel concepts, modalities and medicines to patients globally. Nuclear Medicine also presents unique supply chain production and logistics challenges given the nature of radioisotopes. Full-Life was established by a team of seasoned nuclear medicine, physics and logistics experts in conjunction with global leaders in drug discovery to resolve these challenges for patients.

About Full-Life Technologies

Full-Life Technologies Limited (“Full-Life”) is a fully integrated global radiotherapeutics company with operations in Europe and China. We seek to own the entire value chain for radio-ligand research & development, production & commercialization in order to deliver clinical impact for patients. We plan to attack the core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs & scientists with a demonstrated track record in the life sciences as well as radioisotope research and clinical development.

About Gordian Ventures

Gordian is global life science venture firm focused on the incubation of companies with extremely high technical barriers to entry. Gordian’s team is comprised of successful entrepreneur operators who focus on being a Co-founder to each of the ventures in which it operates / incubates. Gordian is headquartered in Massachusetts with offices in Shanghai, China.

About Chengwei Capital

Founded in 1999, Chengwei Capital is one of the world's leading evergreen funds. Over the past 20 years, Chengwei has been involved in high-end manufacturing, Internet, semiconductor, corporate services, biotechnology, and other areas. Its cumulative total investment exceeds \$2 billion U.S. dollars with more than 100 invested companies. Chengwei is based in Shanghai with offices globally.

Contact Us: pr@t-full.com